PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial

2024-513827-18-00 Protocol VAR2-2024-CS01 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 29 Nov 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol VAR2-2024-CS01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 32
Countries 1
Sites 1

Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

Key facts

Sponsor
Var2 Pharmaceuticals ApS
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
29 Nov 2024 → ongoing
Decision date (initial)
2024-09-24
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

VersionLevelCodeTermSystem organ class
21.1 LLT 10065147 Malignant solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Var2 Pharmaceuticals ApS

Sponsor organisation
Var2 Pharmaceuticals ApS
Address
Ole Maaloees Vej 3
City
Copenhagen N
Postcode
2200
Country
Denmark

Scientific contact point

Organisation
Var2 Pharmaceuticals ApS
Contact name
Ali Salanti

Public contact point

Organisation
Var2 Pharmaceuticals ApS
Contact name
Ali Salanti

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 32 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Universitair Medisch Centrum Groningen
Nuclear Medicine and Molecular Imaging, Hanzeplein 1, 9713 GZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-11-29 2024-12-10

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-12 Netherlands Acceptable
2024-09-24
2024-09-24
2 SUBSTANTIAL MODIFICATION SM-1 2025-02-25 Netherlands Acceptable
2025-03-06
2025-03-07
3 SUBSTANTIAL MODIFICATION SM-2 2025-05-06 Netherlands Acceptable
2025-05-15
2025-05-15
4 SUBSTANTIAL MODIFICATION SM-3 2025-10-30 Netherlands Acceptable
2025-11-27
2025-12-01